Screening for coronary artery disease (CAD), using CT coronary angiography, coronary artery calcium scoring and myocardial perfusion imaging, seems an attractive idea. However, there is considerable uncertainty whether the overall potential benefits outweigh the risks. In a situation where the prevalence of disease is very low, the positive predictive value of any test will tend to be low, and false positive results frequent, requiring a large number of individuals to undergo further testing to confirm disease in a small number of patients. Even when disease is detected, the benefits of revascularisation are uncertain in asymptomatic populations. There is considerable uncertainty about the risks from radiation as a result of imaging tests such as CT scans. Based on available data, the actual risks of malignancy for most individuals appear to be small and of limited concern in a symptomatic patient with a moderate likelihood of disease. However, in a low risk population as in the context of coronary artery screening, the likelihood of benefit is likely to be much smaller due to the lower likelihood of disease, and may well be balanced by the possibility of harm. Screening for CAD using CT coronary angiography, coronary artery calcium scoring and myocardial perfusion imaging should be undertaken only after all these limitations have been properly discussed with the patient, and the patient's global risk of CAD has been estimated using conventional risk scoring. Testing should not be undertaken without careful consideration of whether the test result might change the patient's risk category and plan of management.
INTRODUCTION
Screening for coronary artery disease (CAD) using computed tomography (CT) coronary angiography, coronary artery calcium scoring and myocardial perfusion imaging (MPI) has become an attractive idea akin to screening for cancer. Nevertheless, screening for coronary artery disease with these imaging modalities is not without controversy. CAD is a major cause of mortality worldwide, 1 and sudden death may be the initial presenting symptom. 2 Effective treatment, through risk factor control, medication or coronary revascularisation is well established, 3, 4, 5 and has been shown to reduce the risks of subsequent events or relieve symptoms. 4 CT coronary angiography has been shown to have excellent negative predictive value for coronary artery disease in individuals without known coronary artery disease. 6 It is therefore not surprising that the SHAPE Task Force has advocated population screening for CAD with the use of calcium scoring or ultrasound imaging for carotid intimal media thickening or coronary angiography in selected groups. 7 Despite the appeal of these arguments, major professional societies currently do not encourage the use of screening. The AHA/ACC 8, 9 appropriate use guidelines rates the use of CT angiography in asymptomatic individuals as inappropriate or of uncertain value. The AHA 10, 11, 12 assesses screening for CAD to be a Class III indication (not recommended). Clinical Practice Guidelines 1/2011 published by Proceedings of Singapore Healthcare  Volume 20  Number 4  2011 the Ministry of Health (MOH) Singapore also do not recommend routine screening for CAD in unselected patients. 13 Despite these statements, the use of imaging for CAD detection or screening remains popular.
Ideally, the use of screening should be based on randomised clinical trials, but very few such studies are available. In the absence of such data, this review article will highlight some of the key issues that should be discussed with patients considering the screening test using CT coronary angiography, coronary artery calcium scoring and myocardial perfusion imaging.
RANDOMISED CONTROLLED TRIALS
The case for CAD screening is perhaps strongest for patients with diabetes mellitus, since ischaemic heart disease is by far the greatest cause of death in diabetes, 14 ,15 yet many patients may have silent ischaemia. 16 Myocardial perfusion imaging (MPI) has been shown to have diagnostic and prognostic value in diabetics 17 and there is one retrospective observational study suggesting benefit from revascularisation of diabetics with high risk abnormal single-photon emission computed tomography (SPECT) MPI studies. 18 Therefore, it would seem reasonable to conclude that screening diabetics using MPI would identify such high-risk patients who would then benefit from revascularisation.
Indeed, such a study has been performed. 19 The Detection of Ischaemia in Asymptomatic Diabetics (DIAD) Study randomised over 1,000 patients to a strategy of screening using MPI versus conventional therapy. Of those patients who underwent screening, 22% were found to have asymptomatic ischaemia and 6% severe ischaemia. On the basis of these findings alone, without consideration of the conventional treatment arm, the presumption would be that screening had value, since asymptomatic patients were found to have disease. However, there was no difference in outcomes between the screening arm and the conventional therapy arm after follow-up for about five years. Why was there no benefit? One explanation might be that the survival benefit of revascularisation was limited in the population studied. Indeed, in the Bypass Angioplasty Revascularisation Investigation 2 Diabetes (BARI-2D) trial 20 in which diabetic patients were randomised to revascularisation versus medical therapy, there was no survival benefit with revascularisation, although there was a lower rate of MI but not death in those patients who had more advanced disease who were assigned to bypass surgery. It might be that the benefits of revascularisation were small and difficult to detect in an asymptomatic population. In conclusion, the study failed to show any value in screening asymptomatic diabetics using MPI.
Coronary artery calcium scoring has also been advocated as a method of screening and has demonstrated its role in predicting long-term survival in asymptomatic individuals. 21, 22 This was shown in a registry of 25,253 asymptomatic patients where ten-year survival was 99.4% for calcium score of 0 and 87.8% for a score of >1000 (P<0.0001) after adjustment for risk factors and age. 22 Besides that, according to ACCF/ SCCT/AHA 2010 Guideline, it is appropriate to perform coronary artery calcium scoring among asymptomatic individual who has intermediate risk for CAD or among those at low risk for CAD but has family history of premature coronary artery disease. 9 However, the St Francis study randomised subjects with elevated calcium scores to a regime of lipid-lowering using atorvastatin combined with aspirin versus aspirin alone. 23 The difference in event rates between the treatment arm and the control arm was not statistically significant, though retrospective analysis showed that a calcium score >400 appeared to identify patients who might benefit from lipid lowering.
In addition, based on ACCF/ASNC/ACR/AHA/ASE/ SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging, screening asymptomatic individual with high coronary heart disease (CHD) risk (ATP III risk criteria) is appropriate. However, it is inappropriate to do screening using cardiac radionuclide imaging in an individual with low or intermediate CHD risk if ECG is interpretable. The value of screening is uncertain in those with intermediate CHD risk and uninterpretable ECG. The guidelines also mentioned that it is appropriate to perform cardiac radionuclide imaging in asymptomatic individual with coronary calcium Agatston score >400 or those with Agatston score between 100 and 400 but has high CHD risk. 24 Hence, the role of screening for coronary artery disease using cardiac radionuclide imaging is limited to patients with high CHD risk or those with Agatston score >400 24 (Table 1) .
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In summary, with the limited data available from randomised trials, there is little hard evidence to support widespread and unselected screening for CAD using computed tomography (CT) coronary angiography, coronary artery calcium scoring and myocardial perfusion imaging at present. Of course, absence of such evidence does not totally exclude the possibility that screening might be beneficial. In the absence of such evidence, the best that can be done is to weigh carefully the potential benefits and risks of screening based on available data.
ESTIMATING POTENTIAL BENEFITS FROM SCREENING FOR CAD
In principle, screening for CAD could benefit patients by identifying patients who would a) benefit from revascularisation b) benefit from lipid lowering (which they might otherwise not qualify for), c) benefit from other medical therapy such as antiplatelet therapy with aspirin or d) benefit from being identified at being at risk from strenuous physical exertion. These potential benefits would have to outweigh the potential harms (radiation, misdiagnosis and incidental finding) that might result ( Table 2 ).
In order to weigh the benefits versus risks, one would have to also estimate the prevalence of disease, since the benefits of disease detection accrue only to the patients with disease, whereas the risks of testing apply to the entire population being tested, including those who are free of disease. Indeed, this is a crucial factor; when the condition is relatively common and treatable, the potential for benefit is much larger, and it will be Table 2 . Potential Benefits of Screening For Coronary Artery Disease.
Potential Benefit Recommendation
1. Early detection of anatomically significant CAD with potential for survival benefit with bypass surgery (e.g. left main or triple vessels CAD)
Benefit will depend on frequency of advanced CAD in population being screened; some observational data in diabetics 2. Early detection of asymptomatic CAD with potential for survival benefit with percutaneous coronary intervention (PCI)
No evidence to demonstrate survival benefit from PCI in asymptomatic patients 3. Early detection of asymptomatic patients who will benefit from initiation of lipid lowering or antiplatelet therapy, or more aggressive target for LDL Requires estimation of additional number of events prevented by earlier treatment compared to treatment based on clinical grounds 4. Identification of patients at risk for sudden death who will benefit from avoidance of strenuous physical exertion during sports or military training
Currently no trial data to support, though recommended by some expert guidelines Given that we can estimate the prevalence of disease in a population, and also have some idea of the potential harm from radiation exposure, it should theoretically be possible to estimate the number of patients detected and compare that with some estimate of harm.
For example, although CT coronary angiography is not recommended for screening for CAD (a class III indication in the latest AHA/ACC guidelines 2010), it is widely used in Asia in this regard. No randomised controlled trials exist testing the value of screening for CAD using CT angiography. However, we could estimate the potential number of patients who might benefit from screening with CTA as well as the potential harm from radiation from such testing from one observational study in which 1,000 asymptomatic Korean subjects underwent screening with this technique. 25 In this study, 22% of subjects were found to have asymptomatic atherosclerosis, but only 2% had severe stenoses and 1.4% underwent revascularisation. From this data, can we conclude that screening with CTA is beneficial? In the absence of a control arm, it is difficult to assess the risks versus benefits of screening using CTA. However, for those who underwent revascularisation, only one subject (0.1% of the entire study population) underwent coronary artery bypass surgery (which might conceivably improve survival in the presence of left main or triple vessel disease); the rest underwent coronary angioplasty, which in the COURAGE study 26 did not confer survival benefit. Thus, if one had to estimate potential survival benefit from revascularisation in this population, it appears to be likely to be not more than one per 1000, since only 0.1% of the population underwent coronary artery bypass grafting surgery (CABG). It is difficult to be confident of survival benefit in the patients who underwent angioplasty. Overall there were no subsequent deaths or MIs in the study population.
It could be argued that even the detection of one patient warranting bypass surgery might well be worth screening 1,000 patients with CTA. But that does not take into account the potential risks of screening, such as radiation risks. The risks of radiation are theoretical, based on data extrapolated from atomic bomb survivors, and controversial, given that these are only estimates. However, in situations of uncertainty, it would be reasonable to accept the best available expert advice, which leads us to rely on the BEIR VII estimates of radiation risks. 27 Based on BEIR VII, the lifetime risk of cancer with approximately 10 mSv of radiation exposure (which is approximately the order of magnitude of exposure with conventional 64 slice CT, although this has been significantly lowered recently with newer techniques) is estimated to be in the range of 1 per 1,000 to 1 per 2,000. 28 This varies with the age and gender of the individual.
Given that the likelihood of benefit from revascularisation was earlier estimated at possibly one per 1000 screened in the Korean observational study, it is difficult to be confident that this benefit would clearly outweigh the risks of radiation, which might well be on the order of 1 per 1,000 additional risks of cancer. Both of these numbers are only estimates, and so any conclusions are speculative. However, they serve to highlight the hidden pitfalls in screening.
Recently, the authors of this study published a follow-up study, in which a control group matched to the original screened group, was also studied and compared for outcomes. Though not a randomised trial, the two groups were matched and appeared comparable. The authors found that the use of coronary computed tomographic angiography (CCTA) in asymptomatic patients appeared to lead to increased use of aspirin and statin, increased secondary testing as well as revascularisation. However, there was no difference in cardiac events at 18 months 29 between the two groups.
It could also be hypothesised that earlier detection of CAD could lead to lives saved or myocardial infarcts prevented through use of statins, quite apart from revascularisation. However, many patients who might be candidates for screening might already be eligible for lipid lowering on the basis of their lipid levels, in which case screening for CAD might not change management, and only add cost. The only difference might be the threshold for initiation and the target goal. Hence, to argue that screening for CAD would prevent events would require some estimation of the numbers that would benefit from more aggressive lipid lowering It could also be hypothesised that earlier detection of CAD could lead to lives saved or myocardial infarcts prevented through use of aspirin. Use of aspirin has been shown to reduce the risk of events in secondary prevention (i.e. in patients with known CAD). This benefit has been assumed to also hold true in patients with a high risk of CAD, and hence advocated for use in primary prevention (for example, in diabetics with no known CAD). However, it must be remembered that the benefits of any treatment including one so mild as aspirin, must be weighed against possible risk (e.g. gastrointestinal bleeding). Indeed, the POPADAD study 30 showed no value of aspirin over placebo for primary prevention of CAD. A meta-analysis of aspirin use has also questioned its value in primary prevention. The reasons for this are not clear, but in a low risk population, the small potential benefit of antiplatelet therapy might well be offset by the small risk of gastric irritation and bleeding. Hence the assumption that earlier detection of CAD could lead to lives saved or myocardial infarcts prevented through use of aspirin is open to question.
ESTIMATING POTENTIAL RISK FROM SCREENING Radiation
The major concern from the use of CT is radiation.
Estimating the risk of cancer with radiation is fraught with problems. Available estimates are based on the effects of the nuclear bomb based on the populations exposed to high levels at Nagasaki and Hiroshima, but extrapolated to much lower levels of radiation seen in medical imaging. It is uncertain whether at these low doses, there is any actual risk of cancer, since the incremental risk would be difficult to detect except in very large populations and the long period of monitoring needed to detect cancers make it very hard to prove in any observational study. Based on the best available expert estimates, 27 the additional lifetime risk of cancer is about one per 1,000 exposed for every 10 mSv of exposure, 28 though this is higher for women and lower as the age increases. The lifetime risk of cancer is in the region of 20% so that any additional risk has to be placed in this context. So for example, if the incremental risk of a test is 0.1%, the lifetime risk of cancer is increased from approximately 20% to 20.1%.
Given all these caveats, the small risk of cancer (in the order of 0.1%), and the uncertainty of these risks, it might seem reasonable to dismiss these fears as unfounded, especially since there is a possibility of early detection of a potentially life-threatening condition that could be preventable with early revascularisation. However, when one considers the volume of procedures performed, this is not a trivial concern. Moreover, from our earlier analysis, in the absence of any other trial data, the potential benefit from revascularisation was estimated at possibly one per 1,000 screened. Thus the risks might well negate the benefit (Table 3) . The problem is not that the risks of radiation are well-established. Indeed, they are not. The potential benefits of screening are also not well-established. Given the wide confidence limits, it is difficult to advocate a policy of screening with the available data. Patients requesting screening CT scans should be advised of this potential risk.
This issue would be further compounded if a policy of regular screening every few years were to be advocated.
The Problem of Incidental Findings
Another issue is the relatively high incidence of non-cardiac finding, such as pulmonary nodules 31 that requires further work-up, including serial CT scans. The majority of these nodules are benign, but they can provoke anxiety and further radiation exposure. The Fleischner Society had proposed guidelines of advocating different frequencies of CT scans based upon the size of the nodule and the patient's risk for lung cancer. 32
False Positive Test Results and The Effect of The Prevalence of Disease
Yet another challenge to screening is the problem of false positive results. This is a function of test specificity and disease prevalence. To understand this effect, one must compare the effect of applying a test in a population with a high prevalence of disease to a population with a low prevalence of disease (eg. screening).
For example, assuming that a test has a sensitivity and specificity of 90%, then 10% of subjects without disease will have an abnormal (false positive) result.
In testing 1,000 patients in a clinical setting where the prevalence of disease is relatively high (e.g. 50%), a disease prevalence of 50% means that 500 have the disease and 500 are disease free. Therefore since the sensitivity and specificity are 90%, there will be 0.9 x 500 true positives (450 patients detected) and 0.1 x 500 false positives (50 healthy subjects with abnormal results).
Thus, there will be 450 + 50 abnormal results, of which 450 are true positives (positive predictive value = 450/500 = 90%).
In contrast, in a setting where the prevalence of disease is relatively low, such as in screening, disease prevalence might be 1%, so that in a population of 1,000 subjects, only 10 have disease, and 990 are disease free. Applying a sensitivity and specificity of 90% will mean that 9 of the 10 patients will have an abnormal test result, and 0.1 x 990 = 99 subjects without disease will have false positive results. Thus of the 9 + 99 = 108 people with abnormal results, only 9/108 or 8.3% really have disease; the remaining 91.7% are false positive tests. Note that the test accuracy has not changed, only the prevalence of disease.
What are the consequences of false positive results?
Since it is not possible to differentiate between false and true positives, further testing is required for any abnormal test results. This can include more imaging or coronary angiography, and possibly more radiation exposure. If the false positive rate is high (e.g. 91.7%) as shown in the example above, 12 healthy subjects would be required to undergo further testing after screening in order to detect one subject with real disease.
Increasing test accuracy, particularly specificity, will reduce the size of the problem though not completely eliminate it as long as specificity remains less than 100%. The problem is a function of disease prevalence (increasing as prevalence decreases) and test specificity.
In fact, few tests for CAD achieve a specificity of 90%. Stress ECG treadmill testing has a specificity of approximately 77%. 30 CT angiography has specificity of 83% in detecting ≥50% or ≥70% coronary artery stenosis on a patient-based model. 33
The Impact of New Techniques For Reducing Radiation Dose
Given the issues raised above, it is somewhat easier to reason why screening is not advocated by current guidelines. New advances, however, had led to dramatic reduction of radiation dose with cardiac CT. Prospective "step and shoot" acquisition protocols, ultra-fast helical "flash" acquisitions have demonstrated reductions of up to 80% or more in radiation exposure compared to previous doses which are usually in the range of 10 to 13 mSv with 64 slice MDCT. The implications of these developments on the risks of cancer have yet to be fully described, but they certainly open the possibility that cancer risk is much reduced. Thus these techniques hold the potential for shifting the risk benefit equation very much in favour of screening. However, as the above discussion has highlighted, one should be careful to assume benefit without a careful weighing of factors such as the likelihood of disease in each population, the accuracy of the test used, the likely number of true and false positives, and change in treatment that results.
Costs of Screening
Indeed, the escalating costs of medical imaging in the United States 34, 35 are one of the largest contributors to the American healthcare crisis, and the costs of population screening with imaging are estimated to be enormous. 36 Instead of spending money for screening for coronary artery disease in low risk cohorts, perhaps it is more cost-effective for the money to be utilised for participating in regular exercise and lifestyle modification.
"It's the Patient's Request"
It is sometimes argued that, if a patient is worried about CAD and willing to pay for a test, why should the doctor object? ("Otherwise he will just get the test done by another doctor anyway, and the risks are small"). That is almost equivalent to arguing that a patient who wishes to undergo a medical procedure (e.g. coronary angioplasty), even though he has no clear indication for it (e.g. only a 50% coronary stenosis), should be allowed to have it done ("If we refuse to do it, he can get someone else to do the procedure anyway, and the risks are small"). As doctors, we should not only market what we can do, we must be advocates for our patients and advise them on what is likely to benefit them or cause them harm. Where there is uncertainty of benefit, we must express that concern. Patient autonomy is an important principle, but this principle is best exercised with full disclosure of the potential benefits and risks, and education on the limitations of medical science.
CONCLUSION
Screening for CAD, using CT coronary angiography, coronary artery calcium scoring and myocardial perfusion imaging, appears to be an attractive idea, but on closer examination, there is considerable uncertainty of whether the overall potential benefits outweigh the potential risks. In a situation where the prevalence of disease is very low, the positive predictive value of any test will tend to be low, and false positive results frequent, requiring a large number of individuals to undergo further testing to confirm disease in a small number of patients. This poses unnecessary radiation to individuals without coronary artery disease. Even when disease is detected, the benefits of revascularisation are uncertain in asymptomatic populations, and may well be outweighed by the risks.
With these considerations in mind, screening for CAD using CT coronary angiography, coronary artery calcium scoring and myocardial perfusion imaging should be undertaken only after all these limitations have been properly discussed with the patient, and the patient's global risk of CAD has been estimated using the conventional risk score. The temptation to rely on a single test should be avoided. Testing should not be undertaken without careful consideration of whether the test result might change the patient's risk category and plan of management.
In conclusion, the authors do not recommend CT coronary angiography for screening for CAD. 8, 9 Coronary artery calcium scoring may be advocated for screening for CAD among those at intermediate risk for CAD or among those at low risk for CAD but has family history of premature coronary artery disease. 9 The role of screening for coronary artery disease using cardiac radionuclide imaging should be limited to patients with high CHD risk or those with coronary artery calcium score of >400. 24 
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